23andMe faces an uncertain future — so does your genetic data
Portfolio Pulse from
DNA testing company 23andMe is on the brink of bankruptcy after a significant data breach, plummeting stock value, and potential sale of customer genetic data. With 15 million users' information at risk, the company's uncertain future raises serious privacy concerns, especially since it's not bound by HIPAA regulations.
March 24, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The company's stock has collapsed 99% from its $6 billion peak, with bankruptcy filing imminent and potential data asset sale threatening future viability.
Bankruptcy filing, leadership changes, and potential data asset sale signal severe financial distress that will likely cause further stock price decline.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100